Clinical

Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.

Low serum IgE levels were independently associated with nearly double the risk of developing CLL in a retrospective cohort study of 118,740 adults.

A new approach to posttransplant prophylaxis for graft vs host disease promises to increase access to the procedure to patients from minority groups with blood cancers. Investigators are now studying a lower dose of the treatment to limit toxicity.

There were few incidences of complications in the follow-up period after the MicroShunt was implanted in the patient.

Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, reducing reliance on corticosteroids and minimizing the need for systemic escalation.

Phase 3 data show DOR/ISL matches standard INSTI-based therapy in efficacy and safety, signaling a potential shift in first-line HIV treatment.

Real-world evidence complements clinical trial data by capturing how psoriasis therapies perform across diverse patient populations and treatment contexts in everyday practice.

New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for taxane-naive mCRPC and PARP inhibitors in the hormone-sensitive setting.

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib.

This morning, experts delivered "short and sweet" updates on treatment strategies for common dermatologic conditions.

Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.

It may be possible to detect Richter transformation (RT) years before it actually occurs in patients with chronic or small lymphocytic leukemia, research indicates.

Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy.

Experts at the 2026 AAD Annual Meeting noted that, together, PCP support, community outreach, and teledermatology help reduce care gaps.

Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis.

Experts at the 2026 AAD Annual Meeting explained that teledermatology helps dermatologists manage their workload and expand patient access beyond traditional in-person care.

Adjuvant pembrolizumab maintained recurrence-free survival in resected stage IIB/IIC melanoma without increasing new melanoma risk.

Racial and ethnic disparities in outcomes persist in acute myeloid leukemia, but such disparities may not be tied to the use of tyrosine kinase inhibitors, according to a new report.

Ruxolitinib cream can meaningfully improve skin repigmentation and QOL for patients with vitiligo, but its full benefit depends on improved patient education, guidance, and support for consistent, long-term use.

The study covers the period of 2015-2019 in Germany, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of less toxic BTK inhibitors.

Interim data from the EPCORE-NHL-6 trial show safety outcomes similar to those in the pivotal trial that led to approval for the bispecific T-cell–engaging antibody.

Updated guidelines for CSCC introduce more granular risk stratification and emphasize deeper biopsies to improve staging accuracy and guide decisions about surgery and systemic therapy.

NCCN guideline updates for CSCC emphasize immunotherapy as a cornerstone across disease stages, expanding its role from advanced disease into neoadjuvant and adjuvant settings.

Immunotherapy-related skin adverse events may correlate with improved tumor response and survival, underlining their clinical significance.